longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Pharvaris BV

PHVS

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Top Pharvaris Executive Cashes In on Major Insider Stock Sale

    Tip Ranks·18 hours ago
    PHVS-4.29%
  • Pharvaris Chief Technical Ops Officer Sold Shares Worth Over $1.7M

    TradingView·1 day ago, 05:30 PM
    PHVS-4.29%
  • Wim Souverijns Sells 20,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

    Market Beat·2 days ago, 07:08 PM
    PHVS-4.29%BLK+1.50%
  • Pharvaris Chief Commercial Officer Wim Souverijns sells USD 1.02 million in common shares

    PUBT·2 days ago, 06:07 PM
    PHVS-4.29%
  • PHVS: Oral deucrictibant shows high efficacy and safety for HAE, with launch targeted for April 2024

    Quartr·2 days ago, 01:31 PM
    PHVS-4.29%
  • Weekly Recap | Pharvaris BV +7.86%, Phase 3 meets all endpoints

    Weekly Review·Sep 12 at 06:34 AM
    PHVS-4.29%
  • Pharvaris director Robert Glassman disposes of common shares worth $300,396

    PUBT·Sep 11 at 04:25 PM
    PHVS-4.29%
  • Pharvaris President Lu Peng disposes of USD 610,134 common shares

    PUBT·Sep 9 at 03:21 PM
    PHVS-4.29%
  • Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

    benzinga_article·Sep 9 at 01:04 PM
    IMAX+1.81%VRNS-0.52%
  • Pharvaris: Strong Phase 3 Data for Deucrictibant XR, but Commercial Hurdles Justify Hold Despite Price Target Increase to $44

    Tip Ranks·Sep 9 at 02:25 AM
    PHVS-4.29%
  • Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs

    Unusual Whales·Sep 8 at 07:05 PM
    ROIV-0.53%PHVS-4.29%
  • Pharvaris Affirmed as Emerging Oral HAE Leader on Strong Phase 3 Data; Buy Rating Reiterated with Unchanged $60 Price Target

    Tip Ranks·Sep 8 at 03:45 PM
    PHVS-4.29%
  • PHVS: Deucrictibant XR reduced HAE attacks by 83% and was well-tolerated, with strong quality of life gains

    Quartr·Sep 8 at 03:07 PM
    PHVS-4.29%
  • Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday

    benzinga_article·Sep 8 at 02:03 PM
    - U.S. stocks declined on Tuesday, while several individual companies recorded significant share price increases driven by clinical trial results, earnings guidance updates, and funding agreements. - Roivant Sciences shares jumped 16.3% following positive Phase 2 clinical trial data for mosliciguat, and Pharvaris gained 15.8% after releasing Phase 3 results for deucrictibant. - IonQ raised its 2026 revenue outlook and gained 10.8% following an acquisition, while Rigetti Computing and D-Wave Quantum both secured up to $100 million in federal funding agreements.
    RGTI-1.44%QBTS-3.28%
  • Why Is Pharvaris Stock Soaring Tuesday?

    benzinga_article·Sep 8 at 01:59 PM
    PHVS-4.29%